Group 1 - Company Gilead Sciences-B (01672) announced a placement and subscription agreement on August 19, 2025, involving the sale of 52.4 million shares at a price of HKD 16.45 per share [1][2] - The total number of shares being placed represents approximately 5.44% of the company's issued share capital as of the announcement date, excluding treasury shares [2] - The subscription involves the issuance of 28.82 million new shares, which accounts for about 2.90% of the enlarged share capital post-placement and subscription [2] Group 2 - The placement price of HKD 16.45 per share reflects a discount of approximately 9.9% compared to the closing price of HKD 18.26 on August 18, 2025 [2] - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from approximately 53.38% to 49.45% of the issued share capital, excluding treasury shares [2] - The net proceeds from the subscription are expected to be around HKD 468 million, with about 90% allocated for clinical trial development related to obesity treatments and 10% for general corporate purposes [2]
歌礼制药-B(01672)拟折让约9.9%配股 净筹4.68亿港元